1-2 of 2
Avinash G Desai
Close
Sort by
Journal Articles

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Sameem Abedin, Guru Subramanian Guru Murthy, Aniko Szabo, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash G Desai, Mary M Chen, Alexandra M. Harrington, Ehab L. Atallah
Journal: Blood
Blood (2022) 140 (Supplement 1): 157–158.
https://doi.org/10.1182/blood-2022-157827
Published: 2022
Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Nebu V. Koshy, Patrick Stiff, Camille Abboud, Sr., Benjamin Tomlinson, Sunil Abhyankar, Parameswaran Hari, Zaid S. Al-Kadhimi, George L. Chen, Mitchell Sabloff, Johnnie J. Orozco, James M. Foran, Partow Kebriaei, Katarzyna Joanna Jamieson, Margarida Magalhaes Magalhaes-Silverman, Koen van Besien, Michael W. Schuster, Arjun Law, Moshe Levy, Hillard M Lazarus, Sergio A Giralt, Mark S. Berger, Jennifer A Spross, Avinash G Desai, Vijay Reddy, John M. Pagel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1791.
https://doi.org/10.1182/blood-2021-148497
Published: 2021